Product Description
FMS (Feline McDonough sarcoma oncogene), also known as CSF1R (Colony-stimulating factor 1 receptor) or CD115, is a member of the class III receptor tyrosine kinase (RTK) family that plays a pivotal role in monocyte-macrophage differentiation, proliferation, survival, and innate immunity. FMS binds with high affinity to its ligands such as CSF1 (M-CSF, macrophage colony-stimulating factor) and IL-34 (interleukin-34), leading to activation of downstream signaling pathways including PI3K-AKT, RAS-MAPK, SRC, and PLCγ. Beyond its role in normal hematopoiesis, osteoclastogenesis, and immune surveillance, dysregulation of FMS signaling—through activating mutations, overexpression, or autocrine ligand loops—is closely associated with chronic inflammation, rheumatoid arthritis, osteoporosis, and a variety of malignancies including acute myeloid leukemia, chronic myelomonocytic leukemia, tenosynovial giant cell tumor (TGCT), and metastatic breast and prostate cancer (via tumor-associated macrophage modulation), making it a highly validated target for cancer immunotherapy, inflammatory disease therapy, and drug discovery.
Screeningbio’s FMS Kinase Assay Kit provides a robust, sensitive, and high-throughput platform for quantifying FMS kinase activity and evaluating the potency of tyrosine kinase inhibitors (TKIs).
This kit utilizes the ADP-Glo Kinase Assay platform, a luminescent technology that measures the amount of ADP produced during the kinase reaction.
The assay is performed in two distinct steps:
Kinase Reaction: FMS catalyzes the transfer of a phosphate group from ATP to a specific substrate, resulting in the production of phosphorylated substrate and ADP.
ADP-Glo™ Reagent Addition: After the kinase reaction, the ADP-Glo™ Reagent is added to terminate the reaction and deplete any remaining unreacted ATP.
Kinase Detection: The Kinase Detection Reagent is added to simultaneously convert the produced ADP back into ATP, which is then used by luciferase to generate a luminescent signal.
The light intensity produced is directly proportional to the ADP concentration and, consequently, to the enzymatic activity of the FMS kinase.
Data